Amgen's Phase III Osteoporosis Study Is Company's Largest Clinical Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Clinical trials for Amgen's bone loss therapy AMG 162 will look at the entire spectrum of bone health, VP-R&D Perlmutter says. Phase II studies demonstrated lower incidence of dyspepsia and more rapid absorption than Fosamax, he says.